Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK

BJU International
Richard Olivier FourcadeRamiro Castro

Abstract

To calculate the total cost per patient of prostate cancer treatment and the economic cost burden by stage, in the first year after diagnosis, for five European countries. Data from the Information Management Systems, Inc. database, survival data, expert opinion, published data and unit costs from various published official sources were used to calculate total costs per patient by stage for each country, from a payer's perspective. Diagnostic costs, first surgery, radio-, chemo- and hormonal therapy costs were included. Costs were aggregated for incident cases. The mean direct costs per patient for initial treatment were euro3698 in Germany, euro3256 in Spain, euro3682 in the UK, euro5226 in Italy and euro5851 in France. The total costs for all diagnosed patients in the first year from diagnosis were (million euro) 116.7 (UK), 244 (Germany), 385 (France), 202 (Italy) and 114.6 (Spain). The direct initial healthcare cost burden of the most common non-skin-related male cancer, prostate cancer, in France, Germany, Italy, Spain and the UK is considerable. Given the high and increasing prevalence of prostate cancer due to ageing populations in Europe, and the significant cost burden of the disease, national health policy makers shou...Continue Reading

References

Feb 15, 1995·JAMA : the Journal of the American Medical Association·A L PotoskyB S Kramer
Jul 2, 2003·Drugs & Aging·Alice K DavidGary R Hudes
Aug 2, 2003·Actas urologicas españolas·F Herranz AmoJ Turo Antona
Aug 2, 2003·Actas urologicas españolas·F Herranz AmoJ Turo Antona
Aug 16, 2003·Actas urologicas españolas·F Herranz AmoJ Turo Antona
Jul 28, 2004·Health Policy·Silvana QuagliniUNKNOWN GLADIS Study Group (Guideline Application for the Decision making in Ischemic Stroke)
Feb 9, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J FerlayP Boyle
Feb 13, 2007·International Journal of Radiation Oncology, Biology, Physics·Catherine BuronAlain Livartowski
Aug 24, 2007·The Lancet Oncology·Arduino VerdecchiaUNKNOWN EUROCARE-4 Working Group
Oct 9, 2007·European Urology·Axel HeidenreichUNKNOWN European Association of Urology
Dec 13, 2007·Journal of the National Cancer Institute·Rune KvåleFreddie Bray
Mar 7, 2008·BJU International·Georg BartschUNKNOWN Tyrol Prostate Cancer Screening Group
Apr 22, 2008·The Lancet Oncology·Simon M CollinJenny Donovan
May 23, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Laurent MolinierPascale Grosclaude
May 27, 2009·Prostate Cancer and Prostatic Diseases·C G RoehrbornA Benedict
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayDonald Maxwell Parkin

❮ Previous
Next ❯

Citations

Jul 3, 2013·BMC Health Services Research·Maria KellyHarry Comber
Jul 24, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Steven R FeldmanUsha G Mallya
Dec 19, 2014·Journal of Comparative Effectiveness Research·Axel S MerseburgerDavide Meani
Sep 3, 2011·BJU International·Claus G Roehrborn, Libby K Black
Sep 25, 2015·Der Urologe. Ausg. A·V Lent, M Schultheis
Jul 4, 2015·Health Technology Assessment : HTA·Craig R RamsayThomas B Lam
Jan 8, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·S IannazzoM Perachino
Mar 20, 2018·Dermatology and Therapy·Jose-Manuel CarrascosaRobert Strohal
Oct 10, 2012·British Journal of Clinical Pharmacology·Joëlle M HoebertHubert G M Leufkens
Dec 20, 2013·Journal of Medical Economics·W M HartE Baskin-Bey
Mar 11, 2016·Annals of the Rheumatic Diseases·Thomas DörnerGerd R Burmester
Oct 2, 2015·European Journal of Cancer Care·L G GordonS K Chambers
Mar 18, 2017·Asia-Pacific Journal of Clinical Oncology·Merehau C MervinLouisa G Gordon
Aug 15, 2019·BMC Public Health·Stefan ScholzWolfgang Greiner
Apr 21, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S Oudard, F Courbon

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.